APO RESEARCH · REPORT
Drugs for Schistosomiasis
Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.
Product & engineering
Understand the product.
Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.
Selected research
Industry Research
Drugs for Schistosomiasis Industry Research Report 2026
Market perspective
Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.
Shin Poong, Merck, Bayer, EIPICO, Chandra Bhagat Pharma and Taj Pharmaceuticals are the main manufacturers of drugs for Schistosomiasis.
East Africa is the largest region of drugs for Schistosomiasis, whose market share is about 24%,
Read the full market overview
Followed by West Africa(20%).
Report Scope
This report quantifies the global Drugs for Schistosomiasis market in terms of revenue (US$ million) and, where applicable, sales volume (M Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Drugs for Schistosomiasis Market by Company
Shin Poong
Merck
Bayer
EIPICO
Chandra Bhagat Pharma
Taj Pharmaceuticals
Drugs for Schistosomiasis Segment by Type
Praziquantel
Oxamniquine
Other
Drugs for Schistosomiasis Segment by Application
S. haematobium
S. mansoni
S. japonicum
S. mekongi
S. intercalatum
Drugs for Schistosomiasis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Schistosomiasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs for Schistosomiasis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Schistosomiasis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Drugs for Schistosomiasis manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Drugs for Schistosomiasis by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Drugs for Schistosomiasis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Praziquantel
- Oxamniquine
- Other
Applications
- S. haematobium
- S. mansoni
- S. japonicum
- S. mekongi
- S. intercalatum
Companies covered
- Shin Poong
- Merck
- Bayer
- EIPICO
- Chandra Bhagat Pharma
- Taj Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Drugs for Schistosomiasis Market Size (2021-2032)
- 2.2.2 Global Drugs for Schistosomiasis Sales (2021-2032)
- 2.2.3 Global Drugs for Schistosomiasis Market Average Price (2021-2032)
- 2.3 Drugs for Schistosomiasis by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Praziquantel
- 2.3.3 Oxamniquine
- 2.3.4 Other
- 2.4 Drugs for Schistosomiasis by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 S. haematobium
- 2.4.3 S. mansoni
- 2.4.4 S. japonicum
- 2.4.5 S. mekongi
- 2.4.6 S. intercalatum
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Drugs for Schistosomiasis Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Drugs for Schistosomiasis Sales (M Units) of Manufacturers (2021-2026)
- 3.3 Global Drugs for Schistosomiasis Revenue of Manufacturers (2021-2026)
- 3.4 Global Drugs for Schistosomiasis Average Price by Manufacturers (2021-2026)
- 3.5 Global Drugs for Schistosomiasis Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Drugs for Schistosomiasis, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Drugs for Schistosomiasis, Product Type & Application
- 3.8 Global Manufacturers of Drugs for Schistosomiasis, Established Date
- 3.9 Global Drugs for Schistosomiasis Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Shin Poong
- 4.1.1 Shin Poong Company Information
- 4.1.2 Shin Poong Business Overview
- 4.1.3 Shin Poong Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Shin Poong Drugs for Schistosomiasis Product Portfolio
- 4.1.5 Shin Poong Recent Developments
- 4.2 Merck
- 4.2.1 Merck Company Information
- 4.2.2 Merck Business Overview
- 4.2.3 Merck Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck Drugs for Schistosomiasis Product Portfolio
- 4.2.5 Merck Recent Developments
- 4.3 Bayer
- 4.3.1 Bayer Company Information
- 4.3.2 Bayer Business Overview
- 4.3.3 Bayer Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bayer Drugs for Schistosomiasis Product Portfolio
- 4.3.5 Bayer Recent Developments
- 4.4 EIPICO
- 4.4.1 EIPICO Company Information
- 4.4.2 EIPICO Business Overview
- 4.4.3 EIPICO Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 EIPICO Drugs for Schistosomiasis Product Portfolio
- 4.4.5 EIPICO Recent Developments
- 4.5 Chandra Bhagat Pharma
- 4.5.1 Chandra Bhagat Pharma Company Information
- 4.5.2 Chandra Bhagat Pharma Business Overview
- 4.5.3 Chandra Bhagat Pharma Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Chandra Bhagat Pharma Drugs for Schistosomiasis Product Portfolio
- 4.5.5 Chandra Bhagat Pharma Recent Developments
- 4.6 Taj Pharmaceuticals
- 4.6.1 Taj Pharmaceuticals Company Information
- 4.6.2 Taj Pharmaceuticals Business Overview
- 4.6.3 Taj Pharmaceuticals Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Taj Pharmaceuticals Drugs for Schistosomiasis Product Portfolio
- 4.6.5 Taj Pharmaceuticals Recent Developments
5 Global Drugs for Schistosomiasis Market Scenario by Region
- 5.1 Global Drugs for Schistosomiasis Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Drugs for Schistosomiasis Sales by Region: 2021-2032
- 5.2.1 Global Drugs for Schistosomiasis Sales by Region: 2021-2026
- 5.2.2 Global Drugs for Schistosomiasis Sales by Region: 2027-2032
- 5.3 Global Drugs for Schistosomiasis Revenue by Region: 2021-2032
- 5.3.1 Global Drugs for Schistosomiasis Revenue by Region: 2021-2026
- 5.3.2 Global Drugs for Schistosomiasis Revenue by Region: 2027-2032
- 5.4 North America Drugs for Schistosomiasis Market Facts & Figures by Country
- 5.4.1 North America Drugs for Schistosomiasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Drugs for Schistosomiasis Sales by Country (2021-2032)
- 5.4.3 North America Drugs for Schistosomiasis Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Drugs for Schistosomiasis Market Facts & Figures by Country
- 5.5.1 Europe Drugs for Schistosomiasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Drugs for Schistosomiasis Sales by Country (2021-2032)
- 5.5.3 Europe Drugs for Schistosomiasis Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Drugs for Schistosomiasis Market Facts & Figures by Country
- 5.6.1 Asia Pacific Drugs for Schistosomiasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Drugs for Schistosomiasis Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Drugs for Schistosomiasis Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Drugs for Schistosomiasis Market Facts & Figures by Country
- 5.7.1 South America Drugs for Schistosomiasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Drugs for Schistosomiasis Sales by Country (2021-2032)
- 5.7.3 South America Drugs for Schistosomiasis Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Drugs for Schistosomiasis Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Drugs for Schistosomiasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Drugs for Schistosomiasis Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Drugs for Schistosomiasis Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Drugs for Schistosomiasis Sales by Type (2021-2032)
- 6.1.1 Global Drugs for Schistosomiasis Sales by Type (2021-2032) & (M Units)
- 6.1.2 Global Drugs for Schistosomiasis Sales Market Share by Type (2021-2032)
- 6.2 Global Drugs for Schistosomiasis Revenue by Type (2021-2032)
- 6.2.1 Global Drugs for Schistosomiasis Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Drugs for Schistosomiasis Revenue Market Share by Type (2021-2032)
- 6.3 Global Drugs for Schistosomiasis Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Drugs for Schistosomiasis Sales by Application (2021-2032)
- 7.1.1 Global Drugs for Schistosomiasis Sales by Application (2021-2032) & (M Units)
- 7.1.2 Global Drugs for Schistosomiasis Sales Market Share by Application (2021-2032)
- 7.2 Global Drugs for Schistosomiasis Revenue by Application (2021-2032)
- 7.2.1 Global Drugs for Schistosomiasis Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Drugs for Schistosomiasis Revenue Market Share by Application (2021-2032)
- 7.3 Global Drugs for Schistosomiasis Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Drugs for Schistosomiasis Value Chain Analysis
- 8.1.1 Drugs for Schistosomiasis Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Drugs for Schistosomiasis Production Mode & Process
- 8.2 Drugs for Schistosomiasis Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Drugs for Schistosomiasis Distributors
- 8.2.3 Drugs for Schistosomiasis Customers
9 Global Drugs for Schistosomiasis Analyzing Market Dynamics
- 9.1 Drugs for Schistosomiasis Industry Trends
- 9.2 Drugs for Schistosomiasis Industry Drivers
- 9.3 Drugs for Schistosomiasis Industry Opportunities and Challenges
- 9.4 Drugs for Schistosomiasis Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst